IBB iShares Biotechnology ETF

A bearish engulfing candlestick below resistance on the Biotech ETF $IBB suggesting upside exhaustion. The seasonal rally that is typical between May and September has come to an end. $AMGN $GILD $MRNA

$IBB $LLY $VKTX tax loss selling typically peaks the second week of October with a strong November December rebound for small and mid cap laggards. Not that another reason to buy at these levels is needed.

Biotech and healthcare innovation is having a tough week. Breaking notable nearby support in many of these companies. $IBB $XBI $ARKG

$IBB $SLS $XBI they expected interim 8 months after first enrollee and 3 years before full enrollment……. Interesting opinion

$IBB - Per : "We need a quick recovery back above the yellow & blue line in order for the bull-bio market to stay on course"

$IBB Here's the story: **Darya Shipilova**, 28, a lab worker at the Irkutsk Anti-Plague Research Institute in Siberia, died Oct 2 of severe pneumonia. Colleagues say she broke a test tube with live plague on Sept 25 — but Russia denies it, told WHO there are no plague cases, and calls the cause "pneumonia of unknown origin." Nearly 200 contacts are under medical observation, all reportedly testing negative so far. The incident blew up internationally: Trump said he'll call Putin about it "very soon," Rubio wants more transparency, and the State Department reportedly sent Moscow a formal complaint about withholding information. WHO says the risk to the general public looks low.

$IBB president Trump to talk to Putin about the plague death in Siberia. This is very serious bacteria. All the genetics and vaccines stocks will recover tomorrow.

Notable angst in this range on display for biotech $IBB and $XBI. Bearish engulfing bar and tracking heavier volume. Still contained for now, but follow-through selling below 200 would make this more than just a one-off bad day for the sector.